Heartbeam, Inc. · NASDAQ:BEAT
Heartbeam — Q4 2022 Earnings Presentation
17 slides from Heartbeam's earnings presentation, Mar 16, 2023
Slide 1: Medical Grade Heart Attack Detection
Medical Grade Heart Attack Detection Always with the patient Fourth Quarter and Full Year 2022 Financial Results Conference Call NASDAQ: BEAT March 16, 2023
Slide 2: Disclaimers
Fourth Quarter 2022 Financial Results Conference Call DISCLAIMERS This presentation contains forward-looking statements. All statements other than statements of historical fact contained in this presentation, including statements as to the Company’s future results of operations and financial positio
Slide 3: Agenda
Fourth Quarter 2022 Financial Results Conference Call Agenda • Introduction and Recent Announcements Branislav Vajdic • Product Timelines and Updates, and Partnerships Robert Eno • Model at Scale and Financial Results Rick Brounstein • Closing Summary Branislav Vajdic 30 years of experience in 28 ye
Slide 4: Video: HeartBeam AIMIGo Technology
Fourth Quarter 2022 Financial Results Conference Call Video: HeartBeam AIMIGo™ Technology Video link will open in web browser 4
Slide 5: No Patient Friendly Heart Attack Solution in the Market
Fourth Quarter 2022 Financial Results Conference Call No Patient Friendly Heart Attack Solution in the Market 5
Slide 6: Unlocks Conditions Beyond Arrhythmias
Fourth Quarter 2022 Financial Results Conference Call Unlocks Conditions Beyond Arrhythmias ECG Technology VECG 12-Lead 6-Lead ECG 3-Lead 1-Lead Arrhythmia Medical Grade Cardiac Health Monitoring HeartBeam AIMITM and HeartBeam AIMIGoTM have not yet been evaluated by the FDA and are not approved for
Slide 7: Market Landscape: Substantial Capabilities Beyond Existing Offerings
Fourth Quarter 2022 Financial Results Conference Call Market Landscape Substantial Capabilities Beyond Existing Offerings Heart Attack Detection 12L ECG Capable Integrates history & symptoms Uses Baseline Long Term Use Potential AFib Detection AFlutter Detection HeartBeam AIMITM and HeartBeam AIMIGo
Slide 8: Key Fourth Quarter 2022 and Subsequent Highlights
Fourth Quarter 2022 Financial Results Conference Call Key Fourth Quarter 2022 and Subsequent Highlights • Strategic acquisition of substantially all assets from LIVMOR, including 3 issued United States patents, and the LIVMOR technology, including the Halo+™ Atrial Fibrillation (AF) Detection System
Slide 9: HeartBeam AIMI Updates
Fourth Quarter 2022 Financial Results Conference Call HeartBeam AIMI Updates • Submission of HeartBeam AIMI™ platform to FDA to aid in diagnosis of heart attack in August • Clearance is expected in Q2 2023 and limited market release in Q3 2023 HEARTBEAM AIMI FDA Product Development Q4 2021 Q22022 20
Slide 10: HeartBeam AIMI Software and AIMIGo Revenue Opportunity
Fourth Quarter 2022 Financial Results Conference Call HeartBeam AIMI Software and HeartBeam AIMIGo Revenue Opportunity HEARTBEAM AIMIGo HeartBeam HEARTBEAM AIMI HeartBeam AIMI™ AIMIGo™ HeartBeam will use its own salesforce SOFTWARE SOLUTION HeartBeam will use its own salesforce Excellent alignment w
Slide 11: HeartBeam AIMIGo Product Development and Regulatory Plan
Fourth Quarter 2022 Financial Results Conference Call HeartBeam AIMIGo Product Development and Regulatory Plan 3D Vector ECG FDA 510(K) Credit card-sized GEN 1 HeartBeam collection device Predicate devices identified AIMIGo™ Smartphone app Simple validation study Synthesized baseline + Will provide
Slide 12: HeartBeam AIMIGo Updates
Fourth Quarter 2022 Financial Results Conference Call HeartBeam AIMIGo Updates • Granted patent for signal transformation from VECG to 12-Lead Electrocardiogram (ECG), allowing the HeartBeam AIMIGo credit card-sized device to enable a 12-lead ECG • Partnered with Evolve Manufacturing to build HeartB
Slide 13: HeartBeam AIMIGo Potential Market Segments
Fourth Quarter 2022 Financial Results Conference Call HeartBeam AIMIGo Potential Market Segments Demonstrate Demonstrate Clinical and 12 Lead Secure Unique Cost-Effectiveness Equivalence Reimbursement Advantages Market Segment Who pays Stage 1 Stage 2 Stage 3 Cardiologist in the Cloud Patient Concie
Slide 14: Platform Technology, Deep Product Pipeline
PIPELINE PLATFORM TECHNOLOGY DEEP PRODUCT PIPELINE Next Generation Products Slide 7: add footer: est. FDA clearance HeartBeam AIMIGo 12-lead AI Solution 12-lead ECG Integrated System ECG patch Smartwatch 12-lead recording Fully integrated Predictive 12-lead ECG for 12L ECG system algorithms from hea
Slide 15: Q4 & FY 2022 Financial Highlights
Fourth Quarter 2022 Financial Results Conference Call Q4 & FY 2022 Financial Highlights $ in Thousands Quarters ended December 31, Years ended December 31, 2022 2021 2022 2021 Operating Expenses: General & Administrative $2,099 $1,243 $7,354 $2,030 Research & Development 1,639 96 5,677 255 Total Ope
Slide 16: Closing Summary
Fourth Quarter 2022 Financial Results Conference Call Closing Summary • Well known and previously unsolved problem with a massive worldwide market • LIVMOR acquisition extends HeartBeam’s reach in remote monitoring and detection with full ownership of an existing cutting-edge FDA-cleared product, th
Slide 17: Q&A
Q&A Company Investor Relations Rick Brounstein Chris Tyson Chief Financial Officer Executive Vice President HeartBeam, Inc. MZ North America ir@heartbeam.com Direct: 949-491-8235 BEAT@mzgroup.us www.mzgroup.us www.heartbeam.com 2118 Walsh Avenue, Suite 210 Santa Clara, CA 95050